GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hyperion DeFi HYPD · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.58

+3.61%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hyperion DeFi

From its filings with the US Securities and Exchange Commission

SEC filings

Hyperion DeFi is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker HYPD. The SEC classifies its business as finance services. In the fiscal year to 31 December 2025, it reported revenue of $813,455 and a net loss of $45.3m. At that date it held total assets of $51.8m and shareholders' equity of $41.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 Jan 2018
Employees
41
Head office
3090 NOWITZKI WAY, DALLAS, TX, 75219
Incorporated in
DE
Classification
Finance Services
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Hyunsu JungChief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary, Director, since 2025
  • Mr. David KnoxChief Financial Officer, Treasurer, Secretary
  • Mr. Robert RubensteinGeneral Counsel
  • Mr. Happy WaltersDirector
  • Mr. Michael GeltzeilerIndependent Director$140,000
  • Ms. Rachel JacobsonIndependent Director$133,750
  • Dr. Ellen StrahlmanIndependent Director$145,000
  • Mr. Eric RibnerInvestor Relations, since 2022

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
28
Environment
31
Social
24
Governance
29
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Eyenovia develops MicroLine for presbyopia with microdosed pilocarpine.
  • Eyenovia's Optejet delivery system supports drug-device combinations.
  • Eyenovia's MicroPine targets progressive myopia in children with atropine.

Weaknesses

  • Eyenovia has only 41 employees in a competitive pharmaceutical sector.
  • Eyenovia's IPO was in 2018, limiting recent market traction.
  • Eyenovia's products are still in clinical stages without commercialization.

Opportunities

  • Eyenovia can out-license Optejet for additional ophthalmology indications.
  • Eyenovia may expand MicroLine to treat presbyopia globally.
  • Eyenovia could partner for Mydcombi to enhance eye dilation treatments.

Threats

  • Eyenovia faces competition from established ophthalmology drug developers.
  • Eyenovia's clinical stage products risk regulatory delays in approval.
  • Eyenovia's small team size may hinder rapid product development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.